New bone grafting policy includes Cerapedics' peptide enhanced bone graft — 3 insights

Written by Shayna Korol | March 07, 2019 | Print  |

The International Society for the Advancement of Spine Surgery issued a new bone grafting policy that includes Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.

Three things to know:

1. i-FACTOR is one of two drug-device combination products approved by the FDA through the premarket approval process. It's supported by level 1 data.

2. The combination is designed to induce osteoblast cell proliferation and differentiation to accelerate new bone formation in degenerative disc disease patients.

3. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide technology platform. i-FACTOR incorporates a small peptide as an attachment factor to stimulate the bone healing process.

Click here to see the ISASS bone grafting policy.

More articles on biologics:
Aesculap Biologics reaches halfway mark in clinical trial for knee articular cartilage defects: 5 insights
Global autologous matrix-induced chondrogenesis market to reach $186.4M by 2024 — 3 insights
Dr. Roger Hartl: The biggest opportunity in spinal biologics

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months